What can we help you find?

March 5, 2019 6:37 pm ET

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today priced a $5.0 billion public offering of four series of senior
unsecured notes (collectively, the “Notes”). The Notes include:

$750 million of 2.90% notes due 2024

$1,750 million of 3.40% notes due 2029

$1,000 million of 3.90% notes due 2039

$1,500 million of 4.00% notes due 2049

Merck intends to use the net proceeds from the offering for general
corporate purposes, including without limitation the repayment of
outstanding commercial paper borrowings and other indebtedness with
upcoming maturities. The offering is expected to close on March 7, 2019,
subject to customary closing conditions. Goldman Sachs & Co. LLC, J.P.
Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as the
active joint book-running managers for the offering.

The offering of the Notes is being made pursuant to an effective shelf
registration statement (including a base prospectus) filed with the
Securities and Exchange Commission (the “SEC”). The offering may be made
only by means of a prospectus and related prospectus supplement, copies
of which may be obtained by calling Goldman Sachs & Co. LLC at
1-866-471-2526, J.P. Morgan Securities LLC at 1-212-834-4533 or Morgan
Stanley & Co. LLC at 1-866-718-1649. An electronic copy of the
registration statement and prospectus supplement, together with the base
prospectus, is available on the SEC’s website at www.sec.gov.

This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities described herein, nor
shall there be any sale of these securities in any state or jurisdiction
in which such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
jurisdiction.

About Merck

For more than a century, Merck, a leading global biopharmaceutical
company known as MSD outside of the United States and Canada, has been
inventing for life, bringing forward medicines and vaccines for many of
the world’s most challenging diseases. Through our prescription
medicines, vaccines, biologic therapies and animal health products, we
work with customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment to
increasing access to health care through far-reaching policies, programs
and partnerships. Today, Merck continues to be at the forefront of
research to advance the prevention and treatment of diseases that
threaten people and communities around the world – including cancer,
cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease
and infectious diseases including HIV and Ebola.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the
“company”) includes “forward-looking statements” within the meaning of
the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. Such statements may include, but are not limited to,
the company’s ability to complete the offering and the company’s
expectations for the use of proceeds from the offering. These statements
are based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties. If
underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth
in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties
or delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of the company’s patents
and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking
statements can be found in the company’s 2018 Annual Report on Form 10-K
and the company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Media Contacts:

Pamela Eisele
(267) 305-3558

Jennifer Mauer
(908) 740-1801

Investor Contacts:

Peter Dannenbaum
(908) 740-1037

Courtney Ronaldo
(908) 740-6132